Posted by Michael Wonder on 17 Mar 2021
Health Canada approves Increlex, first and only recombinant human insulin-like growth factor-1 therapy in Canada for the treatment of severe growth failure associated with ultra rare condition in children and adolescents
16 March 2021 - Ipsen Biopharmaceuticals today announced the commercial availability of Increlex (mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency, following its Health Canada approval in December 2020.
Increlex is the first and only recombinant human IGF-1 therapy approved in Canada for children and adolescents with severe primary insulin-like growth factor-1 deficiency, an ultra rare condition that affects the growth of fewer than five people per 10,000 globally.
